FX.co ★ Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis

Renowned investor Warren Buffett, often referred to as the "Oracle of Omaha," famously stated, "The stock market is a device for transferring money from the impatient to the patient." This insight is particularly pertinent in the investing realm, where a patient, long-term strategy can sometimes yield remarkable returns. Here are some healthcare sector stocks highlighted on our platform that reached their 52-week highs yesterday.

**Oculis Holding AG (OCS)**

Based in Switzerland, Oculis is a global biopharmaceutical company focused on developing innovative treatments to preserve and enhance eye health. The company's leading investigational product, OCS-01, is a topical eye drop designed for diabetic macular edema (DME) and for reducing inflammation and pain after cataract surgery. Currently, it is undergoing Phase III clinical trials, named DIAMOND-1 and DIAMOND-2, for diabetic macular edema.

Additionally, the company is advancing OCS-02, a topical biologic anti-TNFa eye drop candidate aimed at treating dry eye disease (DED) and non-infectious anterior uveitis. Positive topline data from a Phase 2b trial, called RELIEF, was reported in June from studies involving subjects showing signs of DED.

Another promising candidate is OCS-05, aimed at treating acute optic neuritis (AON) and other neuro-ophthalmic conditions such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. A Phase IIa proof-of-concept trial, named ACUITY, is currently underway for OCS-05 in patients with acute optic neuritis, with topline data expected this quarter.

When we featured OCS on our site on March 19, 2024, it was trading at $11.62. Yesterday, the stock reached a 52-week high of $15.50, representing an increase of more than 30% from our original publication price.

**Belite Bio Inc (BLTE)**

Belite Bio is a clinical-stage biopharmaceutical firm developing pioneering therapeutics for retinal degenerative eye disorders. Their principal drug candidate, Tinlarebant, is an innovative oral therapy intended to slow disease progression in patients suffering from Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD).

The company is currently conducting a pivotal global Phase III trial for Tinlarebant in adolescent STGD1 subjects, named DRAGON, with interim results expected to be shared this quarter.

We highlighted BLTE to our readers on April 3, 2023, when it was trading at $30. The stock reached a 52-week high of $54.39 yesterday, equating to an 81% rise from our original published price.

**CorMedix Inc. (CRMD)**

CorMedix's leading product, DefenCath, is an innovative antibacterial and antifungal solution developed to prevent catheter-related bloodstream infections (CRBSIs) in patients with end-stage renal disease undergoing hemodialysis through a central venous catheter. Approved by the FDA on November 15, 2023, it was commercially launched in inpatient settings in April 2024, followed by outpatient settings in July 2024.

The company announced yesterday the signing of a new commercial supply agreement with a leading mid-sized dialysis operator to supply DefenCath to dialysis clinics across the U.S.

When CRMD was featured on our site on April 12, 2023, it was trading at around $5.07. Yesterday, the stock hit a 52-week high of $9.79, reflecting a 93% increase from our initially published price.

**Scholar Rock (SRRK)**

Scholar Rock is a late-stage biopharmaceutical company focused on creating novel treatments for conditions such as spinal muscular atrophy and cardiometabolic disorders. Its leading drug candidate, Apitegromab, is a muscle-targeted therapy developed for spinal muscular atrophy. The company plans to submit a U.S. Biologics License Application and a European Union marketing authorisation application for Apitegromab's approval next quarter (Q1 2025).

Yesterday, Scholar Rock announced the pricing of an upsized underwritten public offering of 10.27 million shares of its common stock at a public offering price of $28.25 per share. It also offered pre-funded warrants, at a price of $28.2499 each, in lieu of common stock to select investors. This offering, expected to close on October 10, 2024, is projected to generate approximately $300 million in gross proceeds.

When SRRK was first featured on our platform on September 27, 2023, it was trading at approximately $6.76. The stock attained a 52-week high of $35.38 yesterday, marking a gain of over 420% since our initial publication.

**Revolution Medicines Inc. (RVMD)**

Revolution Medicines is a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers. The RAS oncogene is mutated in nearly 20% of all human cancers and plays a pivotal role in tumor growth and progression.The primary focus of the company's drug development efforts is RMC-6236, which is anticipated to progress to a critical phase III monotherapy trial within this year. This study will target the second-line treatment in individuals with metastatic pancreatic ductal adenocarcinoma. Additionally, there are plans to commence a pivotal study of RMC-6236 in patients previously treated for RAS-mutated non-small cell lung cancer (NSCLC).

RVMD was highlighted on our platform on May 9, 2023, when its stock was valued around $24.17. Remarkably, the stock reached a 52-week high of $50 recently, showcasing a 106% increase from our initial report.

**Soleno Therapeutics Inc. (SLNO)**

Soleno Therapeutics is a biopharmaceutical entity in the clinical development stage, dedicated to creating innovative treatments for rare diseases. Its premier candidate, DCCR (Diazoxide Choline) Extended-Release tablets, is designed for once-daily administration in treating Prader-Willi Syndrome. Currently, DCCR is under priority review by the FDA, with a decision expected by December 27, 2024. At the time we informed our audience about SLNO on May 25, 2023, its stock was at $5.51. It recently peaked at a 52-week high of $56.81, signifying a ninefold surge of 931% from our reported price.

**ADMA Biologics Inc. (ADMA)**

ADMA Biologics operates as a comprehensive biopharmaceutical firm, engaged in the manufacturing and marketing of specialized biologics. In its second-quarter financial disclosure this August, the company projected its revenue for the fiscal years 2024 and 2025. For 2024, ADMA forecasts revenues exceeding $400 million and anticipates a net income over $105 million. Looking forward to 2025, revenue projections are set to surpass $445 million, with net income expected to be in excess of $155 million. We notified our readers about ADMA on February 15, 2024, at a trading price of $5.36. The stock later hit a 52-week peak of $20.92, marking a 290% appreciation from our initial price update.

**Natera Inc. (NTRA)**

Natera is a diagnostics firm providing cell-free DNA testing services, with a specialized focus on oncology, women’s health, and organ health. For 2024, the company predicts total revenue between $1.49 billion and $1.52 billion, with an anticipated gross margin ranging from 54% to 56%. In the preceding year, 2023, Natera's revenue amounted to $1.08 billion, alongside a gross margin of 45.5%. Initially highlighted by us on December 21, 2022, when it was trading at $41.75, and again on August 23, 2024, at $122.82, the stock reached an intraday high of $133.54 recently, ultimately closing at $131.93.

**Harrow Inc. (HROW)**

Harrow is advancing within the pharmaceutical realm with a focus on eye care. The second quarter ending June 30, 2024, showcased both financial and operational advances, with a 46% rise in revenue compared to the corresponding quarter last year, and a 42% increase over the previous quarter. When featured on our platform on February 13, 2024, the stock was valued at $11.32. It has since achieved a 52-week peak of $51.95, translating to a 358% growth from our initial report.

**Travere Therapeutics Inc. (TVTX)**

Travere is a biopharmaceutical company committed to the development of therapeutic solutions for rare kidney and metabolic diseases. Its primary drug, Filspari, received full regulatory approval last month to decelerate kidney function deterioration in adults with primary IgA nephropathy (IgAN) at risk of disease progression. Initially approved for accelerated access in February 2023, Filspari has witnessed consistently growing quarterly sales since its U.S. market launch in the same month. Notified to our audience on August 14, 2024, at a trading price of $8.91, the stock climbed to a 52-week high of $15.61, indicating a 75% gain since our advisory.